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2544 Correspondence JACC Vol. 57, No. 25, 2011
June 21, 2011:2542–6an extensive literature search and pooled 18 studies that reported
the incidence of cardiovascular events after a CCTA examination.
Although we agree with the authors’ conclusion that cardiovascular
events among patients with normal findings on CCTA are rare,
some issues raised our concern.
First, the primary outcome measure—major adverse cardiovas-
cular events (MACE)—was defined as death, myocardial infarc-
tion, or revascularization. We noted that 4 large studies (2–5) did
not report event rates for revascularization (see Table 2 in [1]), nor
did they include revascularization in their definition of MACE.
These reports together contribute 67% (6,434 of 9,592) of all
patients included in this meta-analysis. Unfortunately, this issue is
not mentioned by the authors, and it is unclear to what extent this
was accounted for in the analysis. As acknowledged by the authors,
the observed increased rate of MACE among patients with
coronary artery disease is largely driven by the increased rate of
revascularization. Had all studies included revascularization in
their definition of MACE, the true absolute rates of MACE are
likely to be substantially higher. The effect of this underestimation
on sensitivity, specificity, and the likelihood ratio should be
explored. Even if MACE was defined consistently across all
included studies, the question remains whether MACE including
revascularizations is appropriate as the primary endpoint for the
evaluation of CCTA. As pointed out by the authors, most
revascularization procedures will be initiated based on CCTA
findings, resulting in an overestimation of the predictive value of
CCTA.
Second, Figure 6 represents a Fagan’s nomogram for the
prediction of future MACE by CCTA. The figure legend indi-
cates that the left axis represents the pre-test probability of disease,
whereas the Results section indicates that it represents the pre-test
probability of having future MACE. If using the pre-test proba-
bility of disease, it seems inappropriate to perform Bayesian
revision combining a pre-test probability of disease with a likeli-
hood ratio that applies to the annual rate of MACE, when
calculating the post-test probability of future MACE. If the
pre-test probability estimate in Figure 6 refers to the probability of
future MACE, it remains unclear how this estimate can be
calculated and what time frame is being considered. Assuming a
time-frame of 1 year and given the reported annual event rates of
patients in this report, a hypothetical patient with a 20% pre-test
probability of MACE seems like an unrealistic example.
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Reply
We appreciate the important points of clarification of our meta-
analysis (1) raised by Dr. Genders and colleagues. Combined
endpoints have inherent advantages and limitations both in single
studies and in pooled analyses (2). Because not all studies included
in our analysis had complete follow-up for revascularization, we
first sought to summarize the raw data and then provide a pooled
estimate of individual endpoints and a combined endpoint. We
should emphasize again that revascularization is a “soft” endpoint,
subject to biases such as verification and referral bias more so than
death or myocardial infarction (MI). Use of a combined endpoint
of major adverse cardiovascular events (MACE) (including death,
MI, or revascularization) presents limitations that we evaluated
with subgroup analysis using individual endpoints and a “hard”
MACE (death or MI) endpoint. We have presented the raw data
in an effort at full disclosure and to allow for readers to appraise
each endpoint of their own accord. We agree with Dr. Genders
and colleagues that this limitation should be stated explicitly.
With regard to studies that did not report revascularization,
these were included in the pooled combined endpoint, although as
Genders and colleagues have noted, this underestimates a com-
bined endpoint (MACE) most significantly in the patients with
obstructive coronary disease by cardiac computed tomography
angiography (CCTA). Pooling only studies that reported revascu-
larization (n  12) results in a sensitivity, specificity, and negative
ikelihood ratio of 99.6%, 70%, and 0.006, respectively (for future
ACE). The annual event rates for MACE analyzed in this
anner are 0.08% for normal coronary arteries, 2.5% for nonob-
tructive disease, and 28.2% for any obstructive disease on CCTA,
n contrast to our originally reported 0.17%, 1.4%, and 8.8%
nnual event rates among these groups, respectively. As discussed
y Dr. Genders and colleagues, restricting the study population to
nly those reporting all MACE endpoints results in a higher
stimated pooled annual event rate, but does not qualitatively
hange the sensitivity and other summary statistics. With regard to
he Fagan’s nomogram, we agree that for the term “pre-test
robability of disease,” the use of “disease” is unnecessarily vague in
hat context and could be misinterpreted as angiographic obstruc-
ive disease. However, consistent with the context of our paper, we
re referring to “disease” as clinical adverse cardiovascular out-
omes (death, MI, revascularization). In that regard, a hypothetical
re-test probability of 20% would connote a patient with high
aseline risk, considering, for example, a 24% revascularization rate
n patients with obstructive disease.
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2545JACC Vol. 57, No. 25, 2011 Correspondence
June 21, 2011:2542–6The current literature consistently demonstrates that CCTA
has significant prognostic usefulness; however, because of the
highlighted limitations to the available published data, additional
studies that include longer follow-up durations and detailed
outcome reporting will further clarify the prognostic test parame-
ters of CCTA.
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Alcohol Consumption
and Risk of Atrial Fibrillation
We read with interest the meta-analysis on alcohol consumption
and risk of atrial fibrillation (AF) by Kodama and coworkers (1).
owever, several characteristics of our prior publication that are
entioned in Table 1 of the meta-analysis are in need of
larification (2). First, the Women’s Health Study is a prospective
ohort study among female health professionals in the United
tates, not Switzerland (3). Second, the predominant AF pattern
n the Women’s Health Study is actually paroxysmal AF, not
hronic AF, with about two-thirds of the participants with
ew-onset AF having paroxysmal AF. Third, AF diagnosis was
ot based on participants’ reports, but all cases were confirmed by
edical record review. Based on these corrections, the analyses
tratified by these variables presented in Table 2 should be
odified.
In addition, we would like to suggest an additional analysis for
he authors’ consideration. Although sex did not modify the
elationship between alcohol and AF when the results comparing
xtremes of intake were combined in Table 2, the extreme levels of
lcohol intake were generally lower among women as compared
ith men in these studies. Indeed, prior studies have suggested
hat the level of alcohol intake at which AF risk elevates may be
ubstantially lower among women (about 2 drinks per day) as
ompared with men (about 4 to 5 drinks per day) (2,4,5).Therefore, it would be of interest to see the dose-response
relationship between alcohol consumption and AF risk presented
in Figure 4 stratified by sex.
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Reply
We appreciate Drs. Conen and Albert pointing out data that were
mistakenly extracted from their study (1) in our meta-analysis of
the relationship between alcohol consumption and risk of atrial
fibrillation (AF) (2). We apologize. As a result, we carefully
rechecked all data from all papers included in our meta-analysis. In
addition, we found that, more precisely, AF was ascertained by
electrocardiogram rather than from medical records in the study by
Cohen et al. (3). Also, studies initially cited as conducted in
Sweden by Ruigomez et al. (4,5) were performed in the United
Kingdom.
After correcting these data, we reconducted the stratified
analyses of pooled relative risk of AF for highest alcohol intake
versus lowest alcohol intake according to study characteristics.
Nonsignificant differences in AF risk were observed by geographic
region (1.38 [95% confidence interval (CI): 1.22 to 1.56] in North
America and 1.51 [95% CI: 1.23 to 1.86] in Europe; p  0.85) or
by the dominant AF type (1.42 [95% CI: 1.22 to 1.66] for chronic
AF and 1.78 [95% CI: 1.43 to 2.22] for paroxysmal AF; p 0.11).
When AF was ascertained by medical records, the AF risk was
larger (2.05 [95% CI: 1.20 to 3.53]) than by other methods (1.48
[95% CI: 1.29 to 1.70]), but was without statistical significance
(p  0.34). In total, the influences of the corrections were very
slight.
We agree that it would be desirable to investigate the dose-
response relationship between alcohol consumption and AF risk
with stratification by sex, considering that the level of alcohol
intake at which AF risk elevates may be substantially lower among
women than among men (1). However, the number of eligible
studies for a dose-response analysis is too few (n  9) for such an
investigation. This point might have been addressed as a study
